Pharmaceutical Firms’ Shift to Outsourced Sales Faces a More Complicated Reckoning
Translated from Korean and summarized by DistantNews. Read the original for the full story.
At a glance
News
Named sources
Context piece
- South Korean pharmaceutical companies are increasingly outsourcing sales to contract sales organizations, or CSOs.
- Drug prices, commissions, sales efficiency, management duties and tighter regulation are creating new business challenges for both sides.
South Korean pharmaceutical companies are cutting sales staff and turning to outside contractors, but the shift is becoming harder to calculate. Drugmakers and pharmaceutical sales organizations, known as CSOs, now have more than prices, commissions and sales efficiency to consider.
Responsibility for managing CSOs has emerged as an additional variable, along with tighter regulation. The changing environment is forcing both pharmaceutical companies and their sales contractors to rethink their business strategies.
The Ministry of Health and Welfare and the Korea Pharmaceutical and Bio-Pharma Manufacturers Association held a related event on the 2nd, according to the pharmaceutical industry on the 8th.
About this summary
Originally published by Chosun Ilbo in Korean. Translated, summarized, and contextualized automatically by DistantNews, with a note on how the source frames the story. Not individually reviewed before publishing. How this works.
More Stories
From Our Blog
News in Translation: What Gets Lost, and How We Keep the Framing
Diaspora Media: How Communities Follow News From Home
Traveling Where the Press Is Not Free: How to Read the News There
The Digital Nomad's Guide to Local News
The Same Story, Different Countries: How Coverage Changes at the Border
